posted on 2016-08-08, 00:00authored byB Kong, GB Liu, JA Zhang, XX Fu, WY Xiang, YC Gao, YB Lu, XJ Wu, F Qiu, WD Wang, LL Yi, JX Zhong, ZW Chen, JF Xu
Despite the recent appreciation of interleukin 35 (IL-35) function in inflammatory diseases, little is known for IL-35 response in patients with active tuberculosis (ATB). In the current study, we demonstrated that ATB patients exhibited increases in serum IL-35 and in mRNA expression of both subunits of IL-35 (p35 and EBI3) in white blood cells and peripheral blood mononuclear cells. Consistently, anti-TB drug treatment led to reduction in serum IL-35 level and p35 or EBI3 expression. TB infection was associated with expression of p35 or EBI3 protein in CD4(+) but not CD8(+) T cells. Most p35(+)CD4(+) T cells and EBI3(+)CD4(+) T cells expressed Treg-associated marker CD25. Our findings may be important in understanding immune pathogenesis of TB. IL-35 in the blood may potentially serve as a biomarker for immune status and prognosis in TB.
Funding
This work was supported by grants from
the National Natural Science Foundation of
China (81570009, 81273237, 30972779,
81101553), Natural Science Foundation of
Guangdong Province (2015A030313513),
the Key Project of Science and Technology
Innovation of Education Department of
Guangdong Province (2012KJCX0059), the
Science and Technology Project of Dongguan
(201450715200503), the Science and Technology
Project of Zhanjiang (2013C03012)
and the Science and Technology Innovation
Fund of GDMC (STIF201110, B2012078).